These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 12154036)

  • 21. Novel hydroxamate and anilide derivatives as potent histone deacetylase inhibitors: synthesis and antiproliferative evaluation.
    Bouchain G; Delorme D
    Curr Med Chem; 2003 Nov; 10(22):2359-72. PubMed ID: 14529479
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of KD5170: a novel mercaptoketone-based histone deacetylase inhibitor.
    Payne JE; Bonnefous C; Hassig CA; Symons KT; Guo X; Nguyen PM; Annable T; Wash PL; Hoffman TZ; Rao TS; Shiau AK; Malecha JW; Noble SA; Hager JH; Smith ND
    Bioorg Med Chem Lett; 2008 Dec; 18(23):6093-6. PubMed ID: 18954983
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Keratin 23 (K23), a novel acidic keratin, is highly induced by histone deacetylase inhibitors during differentiation of pancreatic cancer cells.
    Zhang JS; Wang L; Huang H; Nelson M; Smith DI
    Genes Chromosomes Cancer; 2001 Feb; 30(2):123-35. PubMed ID: 11135429
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of (1H)-pyrroles as histone deacetylase inhibitors with antitumoral activity.
    Zubia A; Ropero S; Otaegui D; Ballestar E; Fraga MF; Boix-Chornet M; Berdasco M; Martinez A; Coll-Mulet L; Gil J; Cossío FP; Esteller M
    Oncogene; 2009 Mar; 28(11):1477-84. PubMed ID: 19169274
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The histone deacetylase inhibitor butyrate downregulates cyclin B1 gene expression via a p21/WAF-1-dependent mechanism in human colon cancer cells.
    Archer SY; Johnson J; Kim HJ; Ma Q; Mou H; Daesety V; Meng S; Hodin RA
    Am J Physiol Gastrointest Liver Physiol; 2005 Oct; 289(4):G696-703. PubMed ID: 16160080
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo.
    Butler LM; Agus DB; Scher HI; Higgins B; Rose A; Cordon-Cardo C; Thaler HT; Rifkind RA; Marks PA; Richon VM
    Cancer Res; 2000 Sep; 60(18):5165-70. PubMed ID: 11016644
    [TBL] [Abstract][Full Text] [Related]  

  • 27. HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism.
    Mottet D; Pirotte S; Lamour V; Hagedorn M; Javerzat S; Bikfalvi A; Bellahcène A; Verdin E; Castronovo V
    Oncogene; 2009 Jan; 28(2):243-56. PubMed ID: 18850004
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular and cellular basis for the anti-proliferative effects of the HDAC inhibitor LAQ824.
    Atadja P; Hsu M; Kwon P; Trogani N; Bhalla K; Remiszewski S
    Novartis Found Symp; 2004; 259():249-66; discussion 266-8, 285-8. PubMed ID: 15171259
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Histone deacetylase inhibitor suppression of autoantibody-mediated arthritis in mice via regulation of p16INK4a and p21(WAF1/Cip1) expression.
    Nishida K; Komiyama T; Miyazawa S; Shen ZN; Furumatsu T; Doi H; Yoshida A; Yamana J; Yamamura M; Ninomiya Y; Inoue H; Asahara H
    Arthritis Rheum; 2004 Oct; 50(10):3365-76. PubMed ID: 15476220
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity.
    Komatsu Y; Tomizaki KY; Tsukamoto M; Kato T; Nishino N; Sato S; Yamori T; Tsuruo T; Furumai R; Yoshida M; Horinouchi S; Hayashi H
    Cancer Res; 2001 Jun; 61(11):4459-66. PubMed ID: 11389076
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1.
    Rosato RR; Almenara JA; Grant S
    Cancer Res; 2003 Jul; 63(13):3637-45. PubMed ID: 12839953
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
    Qian DZ; Ren M; Wei Y; Wang X; van de Geijn F; Rasmussen C; Nakanishi O; Sacchi N; Pili R
    Prostate; 2005 Jun; 64(1):20-8. PubMed ID: 15651062
    [TBL] [Abstract][Full Text] [Related]  

  • 33. SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).
    Raeppel S; Zhou N; Gaudette F; Leit S; Paquin I; Larouche G; Moradei O; Fréchette S; Isakovic L; Delorme D; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; Wang J; Besterman JM; Murakami K; Li Z; Vaisburg A
    Bioorg Med Chem Lett; 2009 Feb; 19(3):644-9. PubMed ID: 19114304
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of novel isoform-selective inhibitors within class I histone deacetylases.
    Hu E; Dul E; Sung CM; Chen Z; Kirkpatrick R; Zhang GF; Johanson K; Liu R; Lago A; Hofmann G; Macarron R; de los Frailes M; Perez P; Krawiec J; Winkler J; Jaye M
    J Pharmacol Exp Ther; 2003 Nov; 307(2):720-8. PubMed ID: 12975486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MS-275, a histone deacetylase inhibitor, selectively induces transforming growth factor beta type II receptor expression in human breast cancer cells.
    Lee BI; Park SH; Kim JW; Sausville EA; Kim HT; Nakanishi O; Trepel JB; Kim SJ
    Cancer Res; 2001 Feb; 61(3):931-4. PubMed ID: 11221885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors.
    Saito A; Yamashita T; Mariko Y; Nosaka Y; Tsuchiya K; Ando T; Suzuki T; Tsuruo T; Nakanishi O
    Proc Natl Acad Sci U S A; 1999 Apr; 96(8):4592-7. PubMed ID: 10200307
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors.
    Lu Q; Yang YT; Chen CS; Davis M; Byrd JC; Etherton MR; Umar A; Chen CS
    J Med Chem; 2004 Jan; 47(2):467-74. PubMed ID: 14711316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential response of p53 and p21 on HDAC inhibitor-mediated apoptosis in HCT116 colon cancer cells in vitro and in vivo.
    Zopf S; Neureiter D; Bouralexis S; Abt T; Glaser KB; Okamoto K; Ganslmayer M; Hahn EG; Herold C; Ocker M
    Int J Oncol; 2007 Dec; 31(6):1391-402. PubMed ID: 17982666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Histone deacetylase inhibitors with a primary amide zinc binding group display antitumor activity in xenograft model.
    Attenni B; Ontoria JM; Cruz JC; Rowley M; Schultz-Fademrecht C; Steinkühler C; Jones P
    Bioorg Med Chem Lett; 2009 Jun; 19(11):3081-4. PubMed ID: 19410459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.